Recently,Shenzhen Medgen Life Sciences Co., Ltd.(hereinafter referred to as "Medgen Life Sciences") has completed its first round of financing worth tens of millions of yuan.`, by`Huaxi Yuanyou FundExclusive Investment。Medgen Life Sciences' independently developed new generation of inducible bone repair material series, isChina's First Injectable Artificial Bone, compared with the current market's PLA/PLGA/hydroxyapatite artificial bones, it is more convenient to operate.Better performance in bone conduction and other biological properties, used for filling gaps and fissures in limbs and spinal bones under low load-bearing conditions.; In the early exploratory large animal spinal fusion experiment phase, it demonstrated excellent osteoinductive effects, comparable to autologous bone. The product is currently in the registration stage.Pre-filled Injectable Artificial BoneThe pre-filled injectable artificial bone was independently designed and developed by Medgen Life Sciences, utilizing internationally leading patented technology, with a key focus on facilitating doctors' operations and enhancing patient experience.The product uses animal bone as the raw material. The composition and structure of animal bone are consistent with human bone, retaining a natural porous structure that provides the most crucial scaffolding function in the tissue microenvironment. Compared with the mainstream artificially-pored hydroxyapatite on the market,Its natural porous structure increases the specific surface area of the particles themselves, promoting better cell ingrowth and cell adhesion. When cells adhere to the material surface, the inherent calcium and magnesium ions are beneficial for inducing bone and soft tissue regeneration.。Hydroxyapatite of animal origin possesses excellent biocompatibility and bioactivity, and is processed through a special product technique to effectively remove all organic components, avoiding immune reactions.
Rotator Cuff TearOne of the common tendon injuries in orthopedics/sports medicine, and a current key and challenging focus in clinical practice. The company's core self-developed composite rotator cuff patch addresses the issues of insufficient mechanical strength and the tendency to cause immune rejection found in existing market products, demonstrating excellent repair outcomes. This project has undertaken major technical challenges in Shenzhen.Medgen Life Sciences is a supplier specializing in the research and development of natural porous hydroxyapatite repair materials and long-chain triple-helix collagen materials for orthopedics, sports medicine, dentistry, and medical aesthetics, as well as a comprehensive Class III medical device company.The company has a production plant and R&D center of more than 10,000 square meters in Shenzhen, with over 10 cooperative projects with universities and research institutes. It also owns more than 40 independent intellectual property rights and is recognized as a technology-based small and medium-sized enterprise and a high-tech enterprise by the state.
Medgen Life Sciences Focuses on Novel Regenerative Materials, Offering Self-developed Next-generation Repair and Filling Materials with Higher Biocompatibility to Address Clinical Pain Points Across Multiple Scenarios. The company specializes in animal extraction and possesses a full set of core technologies, emphasizing the sourcing and processing of natural raw materials. It has established itself as a platform company centered on medical aesthetics while spanning across medical aesthetics, orthopedics, sports medicine, and dentistry. On the raw material side, the company independently controls its upstream supply chain to ensure stable, consistent, compliant, and effective raw material supply. In terms of processes, the company masters a complete set of pre-treatment techniques, ensuring the safety of clinical trials and product supply while complying with national regulations. Medgen Life Sciences boasts two major technological platforms: hydroxyapatite regeneration product transformation and biomedical collagen cross-linking technology, providing comprehensive regenerative biomaterial solutions across the entire industry chain.
As of the date of this report, the company's financing history is as follows:
As of the date of this report, the following partial patent information of the company has been queried:
# List of Award-Winning Medical Device Companies
Global Surgical Robotics Industry Awards 2024
Global Medical Technology Innovation Award 2024
Global MedTech Newcomer Award 2024
Global Innovative Medical Device Award 2024
# Overseas Medical Device Giants
#ENChina's Major Medical Device ManufacturersMindray Medical｜Lepu Medical|MicroPort｜Weigao Group|United Imaging Healthcare
